Paper Details

  1. Home
  2. Paper Details

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Author: AkNaziye, AkayBüşra, AkyıldızArif, AlanÖzkan, ArakHacı, AydınalpYasemin, AzizyAbdulmunir, AğdaşGözde, BayramDoğan, BilginBurak, BüyükbayramMehmet Emin, BüyükşimşekMahmut, CanaslanKübra, DemirciAyşe, DerinSümeyra, DursunBengü, ErcelepÖzlem, ErdalGülçin Şahingöz, EryılmazMelek Karakurt, EvrenselTürkkan, GöksuSema Sezgin, GümüşMahmut, GüvenDeniz Can, GüzelHalil Göksel, HendemEngin, KahvecioğluFatma Akdağ, KalkanZiya, KarabulutSenem, KarataşFatih, KefeliUmut, KöşFahriye Tuğba, KılıçkapSaadettin, OrduÇetin, OruçZeynep, PaksoyNail, PaydaşSemra, SakinAbdullah, SalimDerya Kıvrak, SağlamSezer, SelviOğuzhan, SeverNadiye, SeyyarMustafa, TatlıAli Murat, TaştekinDidem, TopçuAtakan, TurnaZeynep Hande, UygunKazım, UğraklıMuzaffer, YalçınŞuayib, YazıcıOzan, YaşarSerkan, YücelKadriye Bir, ÇağlayanMelek, ÇetinBülent, ÇobanEyüp, ÖnSercan, ÖzdemirNuriye, ÖzçelikMelike, ÜnalÇağlar, Ünekİlkay Tuba, ÜrünYüksel, ŞanlıUlus Ali, ŞendurMehmet Ali Nihat, ŞimşekMelih

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

CAPTEM treatment was more effective as a first-line treatment for patients with metastatic neuroendocrine tumors (NETs), with a median progression-free survival (PFS) of 16.1 months and a median overall survival (OS) of 105.8 months. This compared to a median PFS of 7.9 months and a median OS of 47.2 months for second-line treatment, and a median PFS of 9.6 months and a median OS of 24.1 months for third-line or higher treatment.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). METHODS: We conducted a multicenter retrospective study analyzing the data of 308 patients with me...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546829/

データ提供：米国国立医学図書館（NLM）

Exploring the Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

Neuroendocrine tumors (NETs), a complex group of cancers that can affect various organs, often present a significant challenge for treatment. This research investigates the efficacy and safety of a combination therapy involving capecitabine and temozolomide (CAPTEM) in patients with metastatic NETs. The authors conducted a retrospective multicenter study analyzing the data of 308 patients who received CAPTEM treatment between 2010 and 2022. Their findings suggest that CAPTEM may be an effective treatment option for metastatic NETs, particularly in the first-line setting, demonstrating encouraging progression-free survival (PFS) and overall survival (OS) rates. The study also highlights the manageable safety profile of this combination therapy.

CAPTEM: A Promising Treatment Strategy for Metastatic NETs

This research provides evidence for the potential efficacy of CAPTEM as a treatment strategy for metastatic NETs. The study's findings suggest that CAPTEM, especially when used in the first-line setting, can achieve significant PFS and OS rates, offering a promising approach for managing this challenging cancer. The study's findings also suggest a relatively manageable safety profile for CAPTEM, minimizing the incidence of severe side effects. This research could potentially change the landscape of NET treatment, offering a new weapon against this challenging disease.

Navigating the Complexities of NET Treatment

This research highlights the importance of exploring new and effective treatment options for metastatic NETs. The study's findings suggest that CAPTEM could be a valuable addition to the therapeutic arsenal for managing this challenging cancer. However, it's essential to remember that each patient is unique, and the effectiveness of any treatment can vary. As a wise camel traversing the desert of cancer treatment, I encourage you to consult with your healthcare provider to discuss the most appropriate treatment options for your specific situation. Remember, the journey to recovery is a collaborative one, requiring a thoughtful approach and a partnership between patient and healthcare professional.

Dr.Camel's Conclusion

This research provides valuable insights into the potential of CAPTEM as a treatment strategy for metastatic NETs, offering a glimmer of hope for patients seeking effective and safe therapies. It's like finding a refreshing oasis in the desert of cancer treatment, providing a potential source of relief and improved outcomes for those facing this challenge.

Date :
  1. Date Completed 2023-10-04
  2. Date Revised 2023-10-05
Further Info :

Pubmed ID

37676712

DOI: Digital Object Identifier

PMC10546829

Related Literature

Article Analysis
・Side Effects of capecitabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.